Product Description
Mechanisms of Action: CFTR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | United States | Uruguay
Approved Indications: Cystic Fibrosis | Cystic Fibrosis
Known Adverse Events: Dizziness | Headache | Abdominal Pain | Pain Unspecified | Respiratory Tract Infections | Rhinitis | Sinusitis | Diarrhea | Influenza, Human
Company: Vertex
Company Location: BOSTON MA 02210
Company CEO: Reshma Kewalramani
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 27
Highest Development Phases
Phase 3: Cystic Fibrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VX22-121-106 | P3 |
Enrolling by invitation |
Cystic Fibrosis |
2030-10-01 |
41% |
| VX22-121-106 | P3 |
Enrolling by invitation |
Cystic Fibrosis |
2030-10-01 |
41% |
| VX22-121-106 | P3 |
Enrolling by invitation |
Cystic Fibrosis |
2030-10-01 |
41% |
| VX21-121-105 | P3 |
Recruiting |
Cystic Fibrosis |
2030-06-01 |
|
| VX22-445-123 | P3 |
Enrolling by invitation |
Cystic Fibrosis |
2027-09-01 |
|
| VX22-445-123 | P3 |
Unknown Status |
Cystic Fibrosis |
2027-08-19 |